Arvinas, Inc. (ARVN) Tops Q4 EPS by 33c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. META
5. LDOS
6. PLTR
7. CSCO
8. KTOS
9. QQQ
10. DT

Go back to Arvinas, Inc. (ARVN) Tops Q4 EPS by 33c

Arvinas Inc. (ARVN) PT Lowered to $81 at H.C. Wainwright

February 12, 2025 6:44 AM EST

H.C. Wainwright analyst Andrew Fein lowered the price target on Arvinas Inc. (NASDAQ: ARVN) to $81.00 (from $87.00) while maintaining a Buy rating.

The analyst comments "VERITAC-2 trial design differences can impact mPFS outcome. As Arvinas plans to share the Phase 3 data from the vepdeg monotherapy trial in 1Q 2025, we remain encouraged that a CBR of 37.1% and 38.9% in 200 mg QD and 500 mg QD is impressive, and we consider it might result in a competitive mPFS in comparison to the EMERALD data of 3.8 months (elacestrant arm) versus 1.9 months (control).... More